Enliven Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ELVN and other ETFs, options, and stocks.

About ELVN

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002.

CEO

Samuel S. Kintz

CEOSamuel S. Kintz

Employees

Employees62

Headquarters

Boulder, Colorado

HeadquartersBoulder, Colorado

Founded

2019

Founded2019

Employees

Employees62

ELVN Key Statistics

Market cap

829.27M

Market cap829.27M

Price-Earnings ratio

-8.77

Price-Earnings ratio-8.77

Dividend yield

—

Dividend yield—

Average volume

428.25K

Average volume428.25K

High today

—

High today—

Low today

—

Low today—

Open price

$17.07

Open price$17.07

Volume

0.00

Volume0.00

52 Week high

$30.03

52 Week high$30.03

52 Week low

$13.30

52 Week low$13.30

Analyst ratings

100%

of 9 ratings

Buy

100%

Hold

Sell

People also own

Based on the portfolios of people who own ELVN. This list is generated using Robinhood data, and it’s not a recommendation.

Enliven Therapeutics

Why Robinhood?

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. Show more

ELVN Key Statistics

Analyst ratings

100%

People also own

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002.